

ANTIVENOM FOUNDATION

England & Wales · Charity number 1204543

Details

Status Registered

Legal form CIO

Registered 2023-08-31

Register [View on the Charity Commission register](#)

Contact

Address 11 Spring Grove
Godalming
GU7 3SS

Phone 07418023224

Email info@antivenomfoundation.org

Website www.antivenomfoundation.org

Activities

Objects: TO RELIEVE SICKNESS AND TO PRESERVE THE HEALTH OF PEOPLE SUFFERING FROM ANIMAL ENVENOMATION (VENOM POISONING) IN ANY PART OF THE WORLD BY:1. THE PROVISION OF, OR ASSISTING IN THE PROVISION OF, MEDICINES, EQUIPMENT AND SUPPORT SERVICES NOT NORMALLY PROVIDED BY THE STATUTORY AUTHORITIES;2. THE UNDERTAKING OF MEDICAL RESEARCH INTO THE TREATMENT OF ANIMAL ENVENOMATION.3. THE PROVISION OF FINANCIAL ASSISTANCE, SUPPORT AND PRACTICAL ADVICE TO THOSE SUFFERING FROM ANIMAL ENVENOMATION; AND4. ADVANCING THE EDUCATION OF MEDICAL PROFESSIONALS AND THE GENERAL PUBLIC ABOUT ANIMAL ENVENOMATION AND RELATED ISSUES.

Activities: The Antivenom Foundation is the worlds first international antivenom stockpile, that provides lifesaving antivenoms for those bitten by venomous snakes or stung by scorpions. We use our extensive network to connect clinics to expert doctors and vetted antivenom suppliers, working with our partners on the ground to strengthen the health system and improve care for patients.

Classification

- **How:** Provides Advocacy/advice/information, Sponsors Or Undertakes Research, Acts As An Umbrella Or Resource Body
- **What:** Education/training, The Advancement Of Health Or Saving Of Lives, Animals
- **Who:** The General Public/mankind

Geography

- Algeria
- Botswana
- Eswatini
- Jordan
- Lebanon
- Mozambique
- Namibia
- South Africa
- Uganda
- Zambia
- Zimbabwe
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2025-03-31	£3,617	£0	-	-
2024-03-31	£157	£0	-	-

Trustees

Name	Role	Appointed
Faisa Price	Chair	2023-08-31
Alessia Cacioni		2024-01-07
Steven Swallow		2023-08-31

ANTIVENOM FOUNDATION

England & Wales - Charity number 1204543

Accounts



Annual report
30/12/2025

ANNUAL REPORT 2024

DETAILS

Antivenom Foundation	Reg: 1204543
Period start	24/12/2024
Period end	30/12/2025

INTRODUCTION

Snakebite envenoming alone kills an estimated 81,000–138,000 people every year and leaves over 400,000 survivors with permanent disabilities, according to the World Health Organization. Other venomous animals—such as scorpions, spiders, and marine species— can also cause significant harm, particularly in rural and resource-limited settings. The only effective treatment for envenoming is antivenom, but it is difficult to produce, expensive, and often unavailable in regions that need it most. Many areas suffer chronic shortages or have no coverage at all, leaving vulnerable communities without life-saving antidotes.

This year marked another step forward as we continued laying the foundations for our long-term mission to improve access to effective antivenoms in regions where envenomation remains a critical public health challenge. While we are still in the early stages, our efforts have focused on supporting research, regulatory submissions, and building partnerships that will lay the ground for the future.

OBJECTIVES AND ACTIVITIES

Summary of charity purpose

The primary aim of the Antivenom Foundation is to establish the world's first international antivenom stockpile mechanism, ensuring timely access to effective treatments that prevent death and disability caused by bites and stings from venomous animals. In pursuit of this goal, the foundation also works to support patients, physicians, and local organizations, while advancing research, education, and awareness on the issue of animal envenomation.

Summary of main activities

Our goal is ambitious, and we are only at the beginning of what will be a long and challenging journey. In this second year of activity, the foundation has built on last year's progress by supporting initial safety studies in Lebanon, preparing submissions for antivenom approval in sub-Saharan Africa, expanding our network of international experts, and contributing to education and knowledge-sharing initiatives.

Statement on Charity commission guidance on public benefit

The Trustees confirm that, in exercising their powers and duties, they have had due regard to the guidance on public benefit issued by the Charity Commission for England and Wales. The Trustees





Annual report
30/12/2025

are satisfied that the charity's activities have been carried out in a manner that aligns with the public benefit requirement set out in the Charity Commission's guidelines.

In making decisions, the Trustees have considered both the aims and the activities of the charity, ensuring that they are for the public benefit and that the charity's resources are used effectively to further its charitable purposes.

ACHIEVEMENTS AND PERFORMANCE

Summary of main achievements

As with the previous year our main achievements in this period have come from the ability of the foundation to draw on a network of international expert volunteers providing small but meaningful contributions that have made a significant difference on the ground.

Sub-Saharan Africa: Our experts continued to assist the University of Costa Rica with regulatory submissions for antivenom in sub-Saharan Africa—a major focus that required significant time and expertise. As part of this effort, we collaborated with local partners in Eswatini to collect and analyse data from their successful implementation of a new antivenom. Regulatory documents are now ready for submission to the local authorities, pending completion of refurbishments at the production plant to allow inspection.

Regional networks: We strengthened engagement with medical toxicology networks across sub-Saharan Africa, and the MENA region with our volunteers invited to join key expert groups. This is an important step toward understanding challenges on the ground. Additionally, we provided speakers for educational seminars organized by local partners in Eswatini and South Africa, helping to raise awareness and share knowledge.

Levant: We provided administrative support to the American University of Beirut (AUB) for safety testing of a new antivenom formulation. This initial study was very small-scale but successful, identifying important issues related to packaging, logistics, handling, and study design that need resolution before larger trials can proceed. With limited effective antivenoms available for the region, we understand that larger humanitarian organizations are now exploring ways to advance this work as they are desperately in need of an effective antivenom for this region.

FINANCIAL REVIEW

Review of financial position

The Antivenom Foundation is still a start-up charity in the process of setting up, it therefore has not undertaken any substantial fundraising or activities that incurred any expense. Thanks to donation platforms we raised more funds than last year—though still very modest, these resources are being held in reserve until we have sufficient capital to undertake more substantial projects.





Annual report
30/12/2025

Reserves policy

Currently the foundation has no formal reserves policy as we have been focused on supporting activities and have not raised significant funds or incurred any overheads. Should this position change in the future then the trustees will develop a reserves policy as appropriate.

Going concerns

The economic environment continues to present challenges for the charity sector, particularly for start-up organisations like ours. Opportunities for grant funding remain limited, and our international focus on neglected diseases further narrows the pool of potential donors. Antivenom is inherently expensive, meaning substantial funds will need to be raised before we can begin fulfilling our primary objective of providing antivenom to those in need.

Despite these challenges, the foundation operates with minimal overheads and currently incurs no significant expenses. We continue to provide a valuable nucleus that connects local organizations with global experts, enabling progress in research, regulatory processes, and knowledge sharing. While fundraising remains difficult and current reserves are modest, the foundation benefits from a committed team of volunteers who are prepared for the long journey ahead.

For these reasons, the trustees remain confident in the charity's ability to continue operating and advancing its mission over the coming year.

STRUCTURE, GOVERNANCE AND MANAGEMENT

The Antivenom Foundation is a Charitable Incorporated Organisation (CIO) governed by constitution. Trustees are appointed for a term of 3 years by majority resolution passed at a properly convened meeting of the charity trustees. In selecting individuals for appointment as charity trustees, the charity trustees must have regard to the skills, knowledge and experience needed for the effective administration of the CIO.

REFERENCE AND ADMINISTRATIVE DETAILS

Antivenom Foundation (AVF) Reg: 1204543

Address 11 Spring Grove
Godalming
GU7 3SS

Trustees	Active from	Term
Faisa Price	31/8/2023	4 years
Steven Swallow	31/8/2023	3 Years
Alessia Cacioni	7/01/2024	3 years





Annual report
30/12/2025

FUNDS HELD AS CUSTODIAN TRUSTEES ON BEHALF OF OTHERS

Not applicable

DECLARATIONS

The trustees declare that they have approved the trustees' report above.

Trustee: Faisa Price

Trustee: Steven Swallow

Signed: 
7E5E26216188439...

Signed: 
11DECDD7036844D...





CHARITY COMMISSION
FOR ENGLAND AND WALES

Antivenom Foundation

1204543

Receipts and payments accounts

CC16a

For the period
from

12/24/24

To

12/30/25

Section A Receipts and payments

	Unrestricted funds to the nearest £	Restricted funds to the nearest £	Endowment funds to the nearest £	Total funds to the nearest £	Last year to the nearest £
A1 Receipts					
Donations	3,617	-	-	3,617	157
Cash reserve from previous year	157	-	-	157	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
Sub total (Gross income for AR)	3,774	-	-	3,774	157
A2 Asset and investment sales, (see table).					
	-	-	-	-	-
	-	-	-	-	-
Sub total	-	-	-	-	-
Total receipts	3,774	-	-	3,774	157
A3 Payments					
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
Sub total	-	-	-	-	-
A4 Asset and investment purchases, (see table)					
	-	-	-	-	-
	-	-	-	-	-
Sub total	-	-	-	-	-
Total payments	-	-	-	-	-
Net of receipts/(payments)	3,774	-	-	3,774	157
A5 Transfers between funds	-	-	-	-	-
A6 Cash funds last year end	-	-	-	-	-
Cash funds this year end	3,774	-	-	3,774	157

Section B Statement of assets and liabilities at the end of the period

Categories	Details	Unrestricted funds to nearest £	Restricted funds to nearest £	Endowment funds to nearest £
B1 Cash funds	Donations	3,617	-	-
	Cash reserve from previous year	157	-	-
		-	-	-
	Total cash funds	3,774	-	-
	(agree balances with receipts and payments account(s))	OK	OK	OK


Categories	Details	Unrestricted funds to nearest £	Restricted funds to nearest £	Endowment funds to nearest £
B2 Other monetary assets		-	-	-
		-	-	-
		-	-	-
		-	-	-
		-	-	-
		-	-	-

Categories	Details	Fund to which asset belongs	Cost (optional)	Current value (optional)
B3 Investment assets			-	-
			-	-
			-	-
			-	-
			-	-

Categories	Details	Fund to which asset belongs	Cost (optional)	Current value (optional)
B4 Assets retained for the charity's own use			-	-
			-	-
			-	-
			-	-
			-	-
			-	-
			-	-
			-	-

Categories	Details	Fund to which liability relates	Amount due (optional)	When due (optional)
B5 Liabilities			-	
			-	
			-	
			-	
			-	

Signed by one or two trustees on behalf of all the trustees

Signature	Print Name	Date of approval
 <small>DocuSigned by: Faisa Price 7E5E26216188439...</small>	Faisa Price	30/12/2025

ANTIVENOM FOUNDATION

England & Wales - Charity number 1204543

Accounts

Annual report
23/12/2024



ANNUAL REPORT 2024

DETAILS

Antivenom Foundation	Reg: 1204543
Period start	31/08/2023
Period end	23/12/2024

INTRODUCTION

Over 6bn people live with venomous snakes and with ever increasing levels of deforestation and encroachment into their natural habitat, snakebites are inevitable. Every year 5 million people are bitten by venomous snakes, resulting in 80,000-140,000 deaths, and leaving 400,000 with life changing disabilities including amputations and organ failure. Snakebite is a fact of life for rural and indigenous communities and is an occupational hazard for the farmers who grow our coffee, chocolate and other commodities we consume every day. Because the population most affected are young (5-40 years old) and the consequences are severe, the impact of snakebite is disproportionate, with a combined burden of 6-8 million disability adjusted life years (DALYs) lost. This is a toll comparable to diseases such as prostate cancer, cervical cancer, rheumatoid arthritis, viral hepatitis and upper respiratory tract infections.

The tragedy is that treatments for snakebite exist and are highly effective. Antivenom prevents over 90% of morbidity and mortality and is listed as an essential medicine by the WHO, but the supply is in crisis. Less than 30% of the antivenom needed is produced, and 40% of species have no specific treatment. These problems are concentrated in low- and middle-income countries where the import of fake or inappropriate antivenoms means that in some cases up to 90% of the available antivenom is known not to work.

The Antivenom Foundation is a start-up charity with a big ambition: to create the worlds' first international antivenom stockpile. In doing so we hope to enable access to effective antivenoms through procurement mechanisms from vetted suppliers, with wrap around support from our extensive global network of expert volunteers.

OBJECTIVES AND ACTIVITIES

Summary of charity purpose

The primary aim of the Antivenom Foundation is to establish the world's first international antivenom stockpile mechanism to provide effective treatments that prevent death and disability from the bites and stings of venomous animals. In pursuit of this primary goal the Antivenom Foundation has scope to provide support to patients, physicians and local organisations, and to further research, education and awareness on the issue of animal envenomations.



Annual report
23/12/2024



Summary of main activities

The goal of the Antivenom foundation is incredibly ambitious and the trustees are under no illusions as to the long and hard road ahead. In this first year of activity the trustees have focused on setting up the charity and connecting with experts and community leaders.

Due to the international outlook of the charity, we faced significant difficulties in opening a bank account and registering for gift aid. The very lengthy delays and uncertainty we experienced on this front impaired fundraising activity during the period. The trustees applied to several small grant schemes, however, as a start-up charity with an international outlook it has become clear that there do not appear to be any seed funding schemes in the UK that are willing to take a risk with such an early-stage initiative. Going forward the antivenom foundation is going to focus on raising funds from donations to enable the first proof of concept delivery project. Despite the challenges on the set-up and fundraising side, the Antivenom Foundation has had some success through our network of expert volunteers who have had a direct impact on the ground (see achievements and performance).

Statement on Charity commission guidance on public benefit

The Trustees confirm that, in exercising their powers and duties, they have had due regard to the guidance on public benefit issued by the Charity Commission for England and Wales. The Trustees are satisfied that the charity's activities have been carried out in a manner that aligns with the public benefit requirement set out in the Charity Commission's guidelines.

In making decisions, the Trustees have considered both the aims and the activities of the charity, ensuring that they are for the public benefit and that the charity's resources are used effectively to further its charitable purposes.

ACHIEVEMENTS AND PERFORMANCE

Summary of main achievements

Our main achievements in this period have come from the ability of the foundation to draw on our network of international expert volunteers providing small but meaningful contributions that have made a significant difference on the ground.

South Africa and Eswatini had experienced ongoing issues with the supply of effective antivenoms leading to shortages. At the request of officials from the local regulatory authorities (SAHPRA) and local organisations, the Antivenom Foundation provided experts to compile and review the available evidence for alternative antivenoms. This led to the emergency approval (under section 21) of 2 antivenoms. Thanks to this work in obtaining emergency approval, one of these antivenoms was procured and extensively used by local organisations in Eswatini, which in November 2024 [reported their first ever snakebite season with no deaths](#).

Kenya like many countries has a substantial burden of snakebites and unequal access to effective antivenoms. Through our network of contacts, the Antivenom foundation was able to facilitate a



Annual report
23/12/2024



donation of 600 vials (approximately 100-150 treatments) of antivenom by connecting suppliers to the ministry of health in Baringo county, with logistical support for the donation provided by MSF.

Lebanon has long had issues with antivenom availability and suitability. Working with toxicologists at the American University of Beirut (AUB), the Antivenom Foundation has fostered a collaboration with antivenom experts at the University of Costa Rica to develop an effective antivenom for the Middle East and North African (MENA) region. This effort led to a new reformulated antivenom which is due to enter phase 1 safety studies in Lebanon under the supervision of AUB.

FINANCIAL REVIEW

Review of financial position

The Antivenom Foundation is still a start-up charity in the process of setting up, it therefore has not undertaken any substantial fundraising or activities that incurred any expense. In the process of establishing the charity we encountered substantial difficulties in opening a bank account, having been refused a bank account by all the major banks, despite having duly followed their lengthy process. A number of grant applications were made; however, these were all unsuccessful. A modest sum of £157 was raised, primarily from online donation "cashback" platforms. The sums raised are not sufficient to undertake any activities related to the primary aim of the charity to supply antivenom and have therefore been held in reserve.

Reserves policy

To date the foundation has not raised any significant funds and does not incur any overheads so does not have a formal reserves policy. Should this position change in the future then the trustees will develop a reserves policy as appropriate.

Going concerns

The current economic environment has been challenging for the charity sector. As a start-up charity there are very limited opportunities to obtain grant funding, which are further diminished by our international outlook and focus on neglected diseases. Antivenom is expensive; substantial sums will therefore need to be raised before the foundation can start to fulfil its primary objective of providing antivenom to those in need. Nonetheless, the foundation does not currently incur any expenses and provides a valuable nucleus that connects local organisations to experts. Despite the difficulties raising funds, the foundation is supported by dedicated volunteers who are in it for the long term and prepared for a difficult road ahead. The trustees are therefore not concerned about the ability of the charity to continue.

STRUCTURE, GOVERNANCE AND MANAGEMENT

The Antivenom Foundation is a Charitable Incorporated Organisation (CIO) governed by constitution. Trustees are appointed for a term of 3 years by majority resolution passed at a properly convened meeting of the charity trustees. In selecting individuals for appointment as charity trustees, the charity trustees must have regard to the skills, knowledge and experience needed for the effective administration of the CIO.





CHARITY COMMISSION
FOR ENGLAND AND WALES

Antivenom Foundation	1204543
----------------------	---------

CC16a

Receipts and payments accounts			
For the period from	31/8/2023	To	23/12/2024

Section A Receipts and payments

	Unrestricted funds to the nearest £	Restricted funds to the nearest £	Endowment funds to the nearest £	Total funds to the nearest £	Last year to the nearest £
A1 Receipts					
Donations	157	-	-	157	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
Sub total (Gross income for AR)	157	-	-	157	-
A2 Asset and investment sales, (see table).					
	-	-	-	-	-
	-	-	-	-	-
Sub total	-	-	-	-	-
Total receipts	157	-	-	157	-
A3 Payments					
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
Sub total	-	-	-	-	-
A4 Asset and investment purchases, (see table)					
	-	-	-	-	-
	-	-	-	-	-
Sub total	-	-	-	-	-
Total payments	-	-	-	-	-
Net of receipts/(payments)	157	-	-	157	-
A5 Transfers between funds	-	-	-	-	-
A6 Cash funds last year end	-	-	-	-	-
Cash funds this year end	157	-	-	157	-

Section B Statement of assets and liabilities at the end of the period

Categories	Details	Unrestricted funds to nearest £	Restricted funds to nearest £	Endowment funds to nearest £
B1 Cash funds	Donations	157	-	-
		-	-	-
		-	-	-
	Total cash funds	157	-	-
	(agree balances with receipts and payments account(s))	OK	OK	OK


	Details	Unrestricted funds to nearest £	Restricted funds to nearest £	Endowment funds to nearest £
B2 Other monetary assets		-	-	-
		-	-	-
		-	-	-
		-	-	-
		-	-	-
		-	-	-

	Details	Fund to which asset belongs	Cost (optional)	Current value (optional)
B3 Investment assets			-	-
			-	-
			-	-
			-	-
			-	-

	Details	Fund to which asset belongs	Cost (optional)	Current value (optional)
B4 Assets retained for the charity's own use			-	-
			-	-
			-	-
			-	-
			-	-
			-	-
			-	-
			-	-
			-	-

	Details	Fund to which liability relates	Amount due (optional)	When due (optional)
B5 Liabilities			-	
			-	
			-	
			-	
			-	

Signed by one or two trustees on behalf of all the trustees

Signature	Print Name	Date of approval
 <small>7E5E26216188439...</small>	Faisa Price	23/12/2024